IL6R and triple-A syndrome: There were also consistent associations with strong cumulative evidence between rs2228145 and a reduced risk of CHD, atherosclerosis, AAA, rheumatoid arthritis, and inflammatory bowel disease identified by this meta-analysis, findings that suggest targeting the IL-6R is a plausible strategy in cardiovascular and inflammatory diseases.